Emerging options in the treatment of deep vein thrombosis and pulmonary embolism

Blood Reviews

Volumn 25, Issue 5, 2011, Pages 215-221

  Brenner, Benjamin ^a,b   Hoffman, Ron ^a,b  

^a Rambam Health Care Campus ^*  (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Apixaban; Dabigatran; Rivaroxaban; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ANTIDOTE; ANTIVITAMIN K; APIXABAN; BERIPLEX; BETRIXABAN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN ETEXILATE; DAREXABAN; EDOXABAN; ENOXAPARIN; FONDAPARINUX; HEMOSTATIC AGENT; HEPARIN; LETAXABAN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; RECOMBINANT BLOOD CLOTTING FACTOR 10A; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIVAROXABAN; UNCLASSIFIED DRUG; WARFARIN;

ARTICLE; BLEEDING; CAUSE OF DEATH; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MEGADOSE; EUROPEAN UNION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INCIDENCE; LUNG EMBOLISM; MORTALITY; NONHUMAN; ORTHOPEDIC SURGERY; OSTEOPOROSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SECONDARY PREVENTION; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; GUIDELINE ADHERENCE; HUMANS; PULMONARY EMBOLISM; RISK ASSESSMENT; VENOUS THROMBOSIS;

EID: 80051668220     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2011.04.003     Document Type: Article

References (70)

1. Cohen A.T., Agnelli G., Anderson F.A., Arcelus J.I., Bergqvist D., Brecht J.G., et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007, 98:756-764.
2. Heit J.A., Cohen A.T., Anderson F.A. on Behalf of the VTE Impact Assessment Group. Estimated annual number of incident and recurrent, non-fatal and fatal Venous Thromboembolism (VTE) Events in the US. Blood 2005, 106:910a.
3. Prandoni P., Lensing A.W., Cogo A., Cuppini S., Villalta S., Carta M., et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996, 125:1-7.
4. Kearon C. Natural history of venous thromboembolism. Circulation 2003, 107:I22-I30.
5. Kahn S.R., Ginsberg J.S. Relationship between deep venous thrombosis and the postthrombotic syndrome. Arch Intern Med 2004, 164:17-26.
6. Bounameaux H. The novel anticoagulants: entering a new era. Swiss Med Wkly 2009, 139:60-64.
7. Kearon C., Kahn S.R., Agnelli G., Goldhaber S., Raskob G.E., Comerota A.J. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133:454S-545S.
8. Hirsh J., Bauer K.A., Donati M.B., Gould M., Samama M.M., Weitz J.I. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133:141S-159S.
9. Warkentin T.E., Levine M.N., Hirsh J., Horsewood P., Roberts R.S., Gent M., et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995, 332:1330-1335.
10. Griffith G.C., Nichols G., Asher J.D., Flanagan B. Heparin osteoporosis. JAMA 1965, 193:91-94.
11. Kelton J.G., Sheridan D., Santos A., Smith J., Steeves K., Smith C., et al. Heparin-induced thrombocytopenia: laboratory studies. Blood 1988, 72:925-930.
12. Warkentin T.E., Greinacher A., Koster A., Lincoff A.M. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133:340S-380S.
13. Warkentin T.E. Think of HIT. Hematology Am Soc Hematol Educ Program 2006, 408-414.
14. Warkentin T.E., Hayward C.P., Boshkov L.K., Santos A.V., Sheppard J.A., Bode A.P., et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 1994, 84:3691-3699.
15. Wawrzynska L., Tomkowski W.Z., Przedlacki J., Hajduk B., Torbicki A. Changes in bone density during long-term administration of low-molecular-weight heparins or acenocoumarol for secondary prophylaxis of venous thromboembolism. Pathophysiol Haemost Thromb 2003, 33:64-67.
16. Shaughnessy S.G., Young E., Deschamps P., Hirsh J. The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. Blood 1995, 86:1368-1373.
17. Samama M.M., Gerotziafas G.T. Newer anticoagulants in 2009. J Thromb Thrombolysis 2010, 29:92-104.
18. Ansell J., Hirsh J., Hylek E., Jacobson A., Crowther M., Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133:160S-198S.
19. Takahashi H., Wilkinson G.R., Nutescu E.A., Morita T., Ritchie M.D., Scordo M.G., et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 2006, 16:101-110.
20. Kamali F., Khan T.I., King B.P., Frearson R., Kesteven P., Wood P., et al. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther 2004, 75:204-212.
21. Franco V., Polanczyk C.A., Clausell N., Rohde L.E. Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols. Am J Med 2004, 116:651-656.
22. Blann A., Hewitt J., Siddiqui F., Bareford D. Racial background is a determinant of average warfarin dose required to maintain the INR between 2.0 and 3.0. Br J Haematol 1999, 107:207-209.
23. Caprini J.A., Tapson V.F., Hyers T.M., Waldo A.L., Wittkowsky A.K., Friedman R., et al. Treatment of venous thromboembolism: adherence to guidelines and impact of physician knowledge, attitudes, and beliefs. J Vasc Surg 2005, 42:726-733.
24. Arepally G, Bauer KA, Bhatt DL, Merli GJ, Naccarelli GV, Carter RD, et al. The use of antithrombotic therapies in the prevention and treatment of arterial and venous thrombosis: a survey of current knowledge and practice supporting the need for clinical education. Crit Pathw Cardiol 2010; 9: 41-48.
25. Gross C.P., Vogel E.W., Dhond A.J., Marple C.B., Edwards R.A., Hauch O., et al. Factors influencing physicians' reported use of anticoagulation therapy in nonvalvular atrial fibrillation: a cross-sectional survey. Clin Ther 2003, 25:1750-1764.
26. Caprini J.A., Hyers T.M. Compliance with antithrombotic guidelines. Manag Care 2006, 15. 49-50, 53-60, 66.
27. Vats V., Nutescu E.A., Theobald J.C., Wojtynek J.E., Schumock G.T. Survey of hospitals for guidelines, policies, and protocols for anticoagulants. Am J Health Syst Pharm 2007, 64:1203-1208.
28. Jiang X., Crain E.J., Luettgen J.M., Schumacher W.A., Wong P.C. Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro. Thromb Haemost 2009, 101:780-782.
29. Shantsila E., Lip G.Y. Apixaban, an oral, direct inhibitor of activated Factor Xa. Curr Opin Investig Drugs 2008, 9:1020-1033.
30. He K., He B., Grace J.E., Xin B., Zhang D., Pinto D.J., et al. Preclinical pharmacokinetic and metabolism of apixaban, a potent and selective factor Xa inhibitor. Blood 2006, 108:910a.
31. Frost C., Lee L., Li L.Y., Nepal S., Shenker A., Reeves R.A. Apixaban does not affect the pharmacokinetics of digoxin. J Clin Pharmacol 2007, 47:60a.
32. Carreiro J., Ansell J. Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict. Expert Opin Investig Drugs 2008, 17:1937-1945.
33. Luettgen J.M., Bozarth T.A., Bozarth J.M., Barbera F.A., Lam P.Y., Quan M.L., et al. In vitro evaluation of apixaban, a novel, potent, selective and orally bioavailable factor Xa inhibitor. Blood 2006, 108:4130a.
34. Raghavan N., Frost C.E., Yu Z., He K., Zhang H., Humphreys W.G., et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009, 37:74-81.
35. Frost C., Yu Z., Nepal S., Bragat A., Moore K., Shenker A., et al. Apixaban, a direct factor Xa inhibitor: single dose pharmacokinetics and pharmacodynamics of an intravenous formulations. J Clin Pharmacol 2008, 48:1132.
36. Lassen M.R., Raskob G.E., Gallus A., Pineo G., Chen D., Portman R.J. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009, 361:594-604.
37. Lassen M.R., Raskob G.E., Gallus A., Pineo G., Chen D., Hornick P. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010, 375:807-815.
38. Lassen M.R., Gallus A., Raskob G.E., Pineo G., Chen D., Ramirez L.M. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010, 363:2487-2498.
39. Connolly S.J., Eikelboom J., Joyner C., Diener H.C., Hart R., Golitsyn S., et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011, 364:806-817.
40. Perzborn E., Strassburger J., Wilmen A., Pohlmann J., Roehrig S., Schlemmer K.H., et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor. J Thromb Haemost 2005, 3:514-521.
41. Varin R., Mirshahi S., Mirshahi P., Chidiac J., Kierzek G., Marie J-P, et al. Effect of rivaroxaban, an oral direct factor Xa inhibitor, on whole blood clot permeation and thrombolysis: critical role of red blood cells. Blood 2009, 114:1064a.
42. Mueck W., Becka M., Kubitza D., Voith B., Zuehlsdorf M. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor xa inhibitor-in healthy subjects. Int J Clin Pharmacol Ther 2007, 45:335-344.
43. Kubitza D., Becka M., Zuehlsdorf M., Mueck W. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 2006, 46:549-558.
44. Kubitza D., Becka M., Mueck W., Zuehlsdorf M. Rivaroxaban (BAY 59-7939)-an oral, direct Factor Xa inhibitor-has no clinically relevant interaction with naproxen. Br J Clin Pharmacol 2007, 63:469-476.
45. Kubitza D., Becka M., Mueck W., Zuehlsdorf M. Co-administration of rivaroxaban-a novel, oral, direct Factor Xa inhibitor-and clopidogrel in healthy subjects. Eur Heart J 2007, 28:1272a.
46. Kubitza D., Becka M., Mueck W., Zuehlsdorf M. Rivaroxaban-a novel, oral, direct Factor Xa inhibitor has no clinically relevant interaction with acetylsalicylic acid or naproxen. J Thromb Haemost 2007, 5. P-T-659a.
47. Kubitza D., Becka M., Zuehlsdorf M. No interaction between the novel, oral direct Factor Xa inhibitor BAY 59-7939 and digoxin. J Clin Pharmacol 2006, 46:11a.
48. Kubitza D., Mueck W., Becka M. No interaction between rivaroxaban-a novel, oral, direct factor Xa inhibitor-and atorvastatin. Pathophysiol Haemost Thromb 2008, 36:40a.
49. Eriksson B.I., Borris L.C., Friedman R.J., Haas S., Huisman M.V., Kakkar A.K., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008, 358:2765-2775.
50. Kakkar A.K., Brenner B., Dahl O.E., Eriksson B.I., Mouret P., Muntz J., et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008, 372:31-39.
51. Lassen M.R., Ageno W., Borris L.C., Lieberman J.R., Rosencher N., Bandel T.J., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008, 358:2776-2786.
52. Turpie A.G., Lassen M.R., Davidson B.L., Bauer K.A., Gent M., Kwong L.M., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009, 373:1673-1680.
53. Bauersachs R., Berkowitz S.D., Brenner B., Buller H.R., Decousus H., Gallus A.S., et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010, 363:2499-2510.
54. Buller H. Once-daily oral rivaroxaban versus placebo in the long-term prevention of recurrent symptomatic venous thromboembolism. The Einstein-extension study. Blood 2009, 114. LBA-2a.
55. Blech S., Ebner T., Ludwig-Schwellinger E., Stangier J., Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008, 36:386-399.
56. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008, 47:285-295.
57. Eriksson B.I., Dahl O.E., Rosencher N., Kurth A.A., van Dijk C.N., Frostick S.P., et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007, 5:2178-2185.
58. Ginsberg J.S., Davidson B.L., Comp P.C., Francis C.W., Friedman R.J., Huo M.H., et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009, 24:1-9.
59. Eriksson B.I., Dahl O.E., Rosencher N., Kurth A.A., van Dijk C.N., Frostick S.P., et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007, 370:949-956.
60. Schulman S., Kearon C., Kakkar A.K., Mismetti P., Schellong S., Eriksson H., et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009, 361:2342-2352.
61. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151.
62. Pradaxa Prescribing information Boehringer Ingelheim Pharmaceuticals Inc, Available at:, Accessed Dec. 13 2010. http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf.
63. Lu G., Luan P., Hollenbach S. Reconstructed recombinant factor Xa as an antidote to reverse anticoagulation by factor Xa inhibitors. J Thromb Haemost 2009, 7. OC-TH-107a.
64. Perzborn E., Harwardt M. Recombinant Factor VIIa partially reverses the effects of the Factor Xa inhibitor rivaroxaban on thrombin generation, but not the effects of thrombin inhibitors, in vitro. J Thromb Haemost 2007, 5. P-W-640.
65. Gruber A., Marzec U.M., Buetehorn U., Buetehorn U., Hanson S., Perzborn E. Potential of activated prothrombin complex concentrate and activated Factor VII to reverse the anticoagulant effects of rivaroxaban in primates. Blood 2008, 112:3825a.
66. Perzborn E., Trabandt A., Selbach K., Tinel H. Prothrombin complex concentrate reverses the effects of high-dose rivaroxaban in rats. J Thromb Haemost 2009, 7. PP-MO-183.
67. Harder S., Parisius J., Picard-Willems B. Monitoring direct FXa-inhibitors and fondaparinux by Prothrombinase-induced Clotting Time (PiCT): relation to FXa-activity and influence of assay modifications. Thromb Res 2008, 123:396-403.
68. Wong P.C., Crain E.J., Xin B., Wexler R.R., Lam P.Y., Pinto D.J., et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost 2008, 6:820-829.
69. Samama M.M., Martinoli J.L., LeFlem L., Guinet C., Plu-Bureau G., Depasse F., et al. Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost 2010, 103:815-825.
70. Stangier J., Rathgen K., Stahle H., Gansser D., Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007, 64:292-303.